Browse drugs

…for paediatric UC patients appears to yield similar outcomes to Infliximab. Given these findings, weighing cost-effectiveness and the bene…

…re on adalimumab, 39 (32.8%) on secukinumab, and five (4.2%) on bimekizumab. Among those on adalimumab, 96.0% follow a weekly regimen, whil…

…59/81 (72.8%) (AO)/43/327 (13.1%) and 55/327 (16.8%) (NRI) with adalimumab. Initial non-responders/incomplete responders benefited from sw…

… anti-TNF (n=37, 26%), p=0.001.In the presence of antibodies to infliximab, 25 (49%) patients immediately changed to an alternative treatm…

…ifficult intravenous (IV) access requiring a midline insertion. Aspirin 10mg/kg 4 times a day was also started at this time alongside m…

…ever, the development of neutralising antibodies may compromise adalimumab’s efficacy. This study investigated the incidence and clinical …

…-COMPARE, SELECT-PsA 1) assessed the effects of upadacitinib or adalimumab versus placebo on pain in patients with attenuation of inflamma…

…d 97 heavy-light chain pairs through proteogenomic analysis.Our adalimumab anti-idiotype enrichment strategy yielded a polyclonal antibody…

…s with chronic recurrent multifocal osteomyelitis, treated with adalimumab. Both developed severe intracranial complications to sinusitis.…

…y of applying life cycle assessment (LCA) to a biological drug, adalimumab, in order to estimate its carbon footprint and to explore the i…

…faecal calprotectin (r = –0.10, p = 0.62) were not significant. Infliximab cohort: 145 patients (420 determinations), mean age 47 ± 20 yea…

…up of disorders characterised by acute or chronic inflammation. Adalimumab and infliximab are the cornerstones of their pharmacotherapy. T…